Different multitarget kinase inhibitors (MKIs, including alectinib, cabozantinib, lenvatinib, ponatinib, regorafenib, sorafenib, sunitinib, and vandetanib) have been evaluated in LC patients with RET rearrangement. This evidence concerns the gene RET and laryngotracheoesophageal cleft.